Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ cIAP1 Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA547036
Description
This antibody does not cross-react with recombinant human cIAP-2 or XIAP. Reconstitute at 0.2 mg/mL in sterile PBS.
The protein encoded by this gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. This encoded protein inhibits apoptosis induced by serum deprivation and menadione, a potent inducer of free radicals.
Specifications
cIAP1 | |
Polyclonal | |
Unconjugated | |
BIRC2 | |
Api1; Api2; apoptosis inhibitor 1; apoptosis inhibitor 2; AW146227; baculoviral IAP repeat containing 2; baculoviral IAP repeat-containing 2; baculoviral IAP repeat-containing 3; baculoviral IAP repeat-containing protein 2; baculoviral IAP repeat-containing protein 2; putative inhibitor of apoptosis; BIRC2; Birc3; cellular inhibitor of apoptosis 1; cIAP1; C-IAP1; cIAP2; HIAP1; HIAP2; Hiap-2; IAP homolog B; IAP1; IAP2; IAP-2; inhibitor of apoptosis protein; inhibitor of apoptosis protein 2; LOC100622859; mcIAP1; MIAP1; MIAP2; mIAP-2; MIHB; MIHC; NFR2-TRAF signalling complex protein; rIAP1; RING finger protein 48; RING-type E3 ubiquitin transferase BIRC2; RNF48; TNFR2-TRAF-signaling complex protein 2 | |
Goat | |
Antigen affinity chromatography | |
RUO | |
329 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.2 mg/mL | |
PBS with 5% trehalose and No Preservative | |
Q13490 | |
BIRC2 | |
E. coli-derived recombinant human cIAP-1/HIAP-2 His2-Ser618. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction